2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.07 Envafolimab Combined with Recombinant Human Endostatin and Chemotherapy for NSCLC

Pdf Summary

A phase II clinical study was conducted at Shandong First Medical University Affiliated Cancer Hospital to evaluate the efficacy and safety of a novel first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC). From April 2022 to August 2023, 29 patients diagnosed with stage IV NSCLC, excluding those with driver mutations, were enrolled. The study focused on combining Envafolimab, a subcutaneously injected PD-L1 inhibitor, with Recombinant Human Endostatin (Rh-endostatin) and platinum-based chemotherapy.<br /><br />Among the 29 participants, 14 had squamous cell carcinoma, while 15 had non-squamous NSCLC. The objective response rate (ORR) was noted at 72.4% (95% confidence interval [CI], 56.1%-88.7%), and the disease control rate (DCR) was 93.1% (95% CI, 76.8%-109.4%). The responses were noteworthy compared to past results, though median progression-free survival (PFS) and overall survival (OS) had not been reached at the time of assessment.<br /><br />Envafolimab combined with Rh-endostatin demonstrated favorable efficacy and appeared to be a promising treatment regimen with a manageable safety profile. Recorded adverse events were mild, with no grade 3 treatment-related adverse events or immune-related adverse events reported.<br /><br />The study's eligibility criteria included patients aged 18-75 years with ECOG performance status 0 or 1. The treatment regimen involved 4-6 cycles of Envafolimab and Rh-endostatin administered every three weeks, followed by maintenance therapy until disease progression or unacceptable toxicity.<br /><br />Funded by Simcere Zaiming Pharmaceutical Co., Ltd., the study showed promising results, warranting further investigation into the treatment combination's potential benefits in advanced NSCLC without driver mutations. There were no conflicts of interest declared by the authors.

Asset Subtitle

Chuanwang Miao

Meta Tag

Speaker Chuanwang Miao

Topic Metastatic NSCLC – Immunotherapy

Keywords

Phase II clinical study

Shandong First Medical University

Non-Small Cell Lung Cancer

Envafolimab

Recombinant Human Endostatin

platinum-based chemotherapy

objective response rate

disease control rate

advanced NSCLC treatment

Simcere Zaiming Pharmaceutical